Dr. Favret on Extending Survival and Improving Outcomes in Breast Cancer

Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.

Anne Favret, MD, medical oncologist and co-director of Breast Research at Virginia Cancer Specialists, discusses the importance of clinical trials in the breast cancer space.

Breast cancer treatment is a marathon, not a sprint, says Favret. Often, women with breast cancer will live for a long time and so regimens that help maintain best quality of life and also extend life are necessary; this is always a challenge, adds Favret. Additionally, being able to recognize new data and incorporate that information into new trials can help to extend the methods that are available for use; that is clinically very important, concludes Favret.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content